DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Tran H, Brighton T, Grigg A. , et al.
A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
Br J Haematol 2014;
167 (02) 243-251
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.